NVO · Novo Nordisk A/S

Novo Nordisk's announcement of topline results from the pivotal HIBISCUS phase 3 trial represents a major milestone for etavopivat, a first-in-class oral pyruvate kinase-R activator for sickle cell disease (SCD), affecting around 8 million people worldwide. The trial, involving 385 participants aged 12+ on standard of care, demonstrated etavopivat's superior efficacy over placebo in reducing annualized vaso-occlusive crisis (VOC) rates by 27% via negative binomial regression and achieving hemoglobin response >1g/dL in 48.7% of patients (adjusted difference 41.2%) at week 24. Time to first VOC was substantially delayed, underscoring potential disease-modifying benefits through improved Hb-oxygen affinity and RBC survival. Safety was favorable, aligning with prior studies, supporting regulatory pursuit. With FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, plus EMA Orphan status, and acquired via 2022 Forma Therapeutics deal, etavopivat positions Novo Nordisk to address unmet needs in SCD, where patients face limited options, pain, and reduced lifespan. Planned H2 2026 submission and upcoming detailed data presentation signal near-term commercialization potential, enhancing Novo Nordisk's pipeline in rare diseases and health equity initiatives.